Cell-Free DNA Identifies Liver Transplant Patients with Acute Rejection
|
By LabMedica International staff writers Posted on 04 Aug 2016 |

Image: A Cell-Free DNA BCT collection tube (Photo courtesy of Streck / Pathology Associates Medical Laboratory).
A cell-free DNA (cfDNA) test could help liver transplant patients receive crucial treatment for rejection faster, and has the potential to improve the prognosis of kidney and heart transplant patients as well.
Episodes of acute rejection, that is rejection that takes place in the first few months after an organ transplant, are relatively common. In liver transplant patients in particular, acute rejection develops in about 20% of those treated with standard immunosuppressive therapy. The gold standard for identifying rejection is biopsy, which is expensive and invasive, and at present there are no effective blood tests to take its place.
Scientists at Chronix Biomedical (Göttingen, Germany) and their associates determined whether a blood test for graft-derived cell-free DNA, which is cell-free DNA from a transplanted organ, could identify liver transplant patients with acute rejection. In a first-of-its-kind prospective multicenter trial, they monitored graft-derived cell-free DNA in the blood of 106 adult liver transplant recipients for at least one year post transplant. . Cell-free DNA was extracted from equal to or more than 1 mL EDTA plasma, obtained in Cell-free DNA-BCT tubes (Streck, Omaha, NE, USA). The turn-around time for an initial sample is about two days and one working day for any consecutive sample.
The teams found that in the 87 stable patients with no signs of graft injury and who were negative for hepatitis C virus infection, the median graft-derived cell-free DNA percentage decreased within the first week to a baseline level of less than 10% of total cell-free DNA concentrations. However, in the 20 patients with samples drawn during biopsy-proven acute rejection periods, graft-derived cell-free DNA levels were about 10-fold higher than those observed in the stable patients.
Overall they determined that by testing for graft-derived cell-free DNA levels of more than 10%, they were able to identify more than 90% of liver transplant patients with acute rejection, which was a substantially higher percentage than what conventional liver function tests can identify. They also believe that this test could detect heart and kidney transplant rejection, and are conducting additional studies to confirm this.
Ekkehard Schütz, MD, PhD, the senior author of the study, said, “This is really a universal test, you can use it for all kinds of solid organ transplantation since it’s just detecting the graft DNA, and it’s independent of what graft you are looking at. It will allow us to start treating these patients as early as possible, which not only impacts the acute situation that the patient is suffering at the time, but also impacts the long term survival of the graft. If we are able to diagnose rejection quickly enough, within a day or one and a half days, and the treating physician can react, then we can avoid really high-grade rejections further down the line.” The study was presented at the 68th American Association of Clinical Chemistry (AACC) Annual Scientific Meeting held July 31 to August 4, 2016, in Philadelphia, PA, USA.
Related Links:
Chronix Biomedical
Streck
American Association of Clinical Chemistry
Episodes of acute rejection, that is rejection that takes place in the first few months after an organ transplant, are relatively common. In liver transplant patients in particular, acute rejection develops in about 20% of those treated with standard immunosuppressive therapy. The gold standard for identifying rejection is biopsy, which is expensive and invasive, and at present there are no effective blood tests to take its place.
Scientists at Chronix Biomedical (Göttingen, Germany) and their associates determined whether a blood test for graft-derived cell-free DNA, which is cell-free DNA from a transplanted organ, could identify liver transplant patients with acute rejection. In a first-of-its-kind prospective multicenter trial, they monitored graft-derived cell-free DNA in the blood of 106 adult liver transplant recipients for at least one year post transplant. . Cell-free DNA was extracted from equal to or more than 1 mL EDTA plasma, obtained in Cell-free DNA-BCT tubes (Streck, Omaha, NE, USA). The turn-around time for an initial sample is about two days and one working day for any consecutive sample.
The teams found that in the 87 stable patients with no signs of graft injury and who were negative for hepatitis C virus infection, the median graft-derived cell-free DNA percentage decreased within the first week to a baseline level of less than 10% of total cell-free DNA concentrations. However, in the 20 patients with samples drawn during biopsy-proven acute rejection periods, graft-derived cell-free DNA levels were about 10-fold higher than those observed in the stable patients.
Overall they determined that by testing for graft-derived cell-free DNA levels of more than 10%, they were able to identify more than 90% of liver transplant patients with acute rejection, which was a substantially higher percentage than what conventional liver function tests can identify. They also believe that this test could detect heart and kidney transplant rejection, and are conducting additional studies to confirm this.
Ekkehard Schütz, MD, PhD, the senior author of the study, said, “This is really a universal test, you can use it for all kinds of solid organ transplantation since it’s just detecting the graft DNA, and it’s independent of what graft you are looking at. It will allow us to start treating these patients as early as possible, which not only impacts the acute situation that the patient is suffering at the time, but also impacts the long term survival of the graft. If we are able to diagnose rejection quickly enough, within a day or one and a half days, and the treating physician can react, then we can avoid really high-grade rejections further down the line.” The study was presented at the 68th American Association of Clinical Chemistry (AACC) Annual Scientific Meeting held July 31 to August 4, 2016, in Philadelphia, PA, USA.
Related Links:
Chronix Biomedical
Streck
American Association of Clinical Chemistry
Latest AACC 2016 News
- Molecular Test Detects Three Arboviruses in Plasma Samples
- Derived Exosomal Protein Biomarkers in Alzheimer’s Disease Diagnosis
- New Biochip Array Developed for ApoE4 Classification
- New Method Tested for Early Diagnosis Pediatric Diabetic Nephropathy
- FDA-Cleared Automated Cell Counter for CSF Launched at AACC 2016
- Semen Analysis Portfolio with Two New Products Featured at AACC 2016
- Automation Solutions for Clinical Diagnostic Equipment Showcased at AACC 2016
- New Tubes Designed for Medium Sample Volumes
- Multi Sample Osmometer Improves Testing Efficiency
- Innovative Information System Optimizes Laboratory Processes
- Innovative eLearning Interface Seamlessly Connects Competency Data
- Cloud-Based Connectivity Platform Advances Decentralized Healthcare
- Adhesives Research to Present Hydrophilic Adhesive Technologies
- Point-of-Care Immunoassay Analyzer on Display at AACC Annual Meeting
- Assay for Determination of 17-OH Progesterone to Be Featured at AACC Annual Meeting
- Fully Automated HbA1c Analyzer Available for Inspection at AACC Annual Meeting
Channels
Clinical Chemistry
view channelAI and Nanotechnology Enable Five-Minute Urine Drug Screening
Rapid screening for illicit drugs remains challenging when testing must be performed at the point of care. Laboratory methods provide accurate results but require sample preparation and specialized equipment,... Read more
Study Questions Uniform Stool-Test Cutoff Across Age Groups
Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read moreMolecular Diagnostics
view channel
Blood RNA Patterns Linked to CAR T-Cell Response and Survival in Lymphoma
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, which involves engineering a patient’s own immune cells to recognize and attack cancer cells, has transformed treatment for large B-cell lymphoma,... Read moreGenome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
Recurrent pregnancy loss, defined as two or more miscarriages, affects about 5% of couples. In many cases, routine evaluation does not identify a cause, particularly when pregnancies have a normal chromosome... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
WHO Survey Reveals Gaps in Antimicrobial Resistance Testing and Response
Antimicrobial resistance (AMR) remains a major challenge for health systems, limiting effective treatment options for drug-resistant infections. These infections caused more than 1 million deaths and contributed... Read more
Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours
Pneumonia is a leading cause of sepsis and is associated with high mortality. Conventional culture-based pathogen identification and antimicrobial susceptibility testing can take two to four days, delaying... Read morePathology
view channel
Researchers Evaluate Automated Tissue Analysis Across Four Cancer Types
Histopathology image analysis plays a central role in cancer diagnosis, but tumor tissue can vary considerably across different regions of the same specimen. Pathologists examine cellular morphology, nuclear... Read more
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
Experimental Blood Test Detects Markers of Three Cancers and Alzheimer’s Disease
Colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer’s disease are serious conditions in which earlier detection may improve clinical outcomes. Blood-based testing could help identify dis... Read more
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more








.jpg)